Special Issue

Protein Regulatory Mechanisms in Tumorigenesis

Message from the Guest Editors

Post-translational modifications play an indispensable role in proper protein quality and functional control. Thus, understanding post-translational protein modifications in normal physiology and pathological conditions not only expands our knowledge on the diversity of the proteome, but also sheds new light on potential therapeutic opportunities. Most protein posttranslational modifications are reversible and dynamically occur in a timely and spatially dependent manner. Abnormal post-translational protein modification events result in deregulated cell signaling, genome instability, and other aberrant biological processes, contributing to the development of human diseases, including cancers. Prior efforts in developing small-molecule inhibitors targeting aberrantly activated enzymes such as kinases show promise for cancer treatment. We hope this collection advances our understanding of the post-translational protein modification events driving disease and their regulatory mechanisms, in order to facilitate the identification of novel drug targets with potential for the development of novel therapies.

Guest Editors

Dr. Penada Liu

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Dr. Wenjian Gan

Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139811

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

